Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3Mixtatin vs Metapex for Irreversible Pulpitis in Primary Molars
NCT06925490Phase 1Not yet recruiting
- Sponsor
- Cairo University
- Start
- Jun 2025
- Primary completion
- Sep 2026
- Modality
- Small Molecules
01
Overview
Phase 1, randomised trial of 3Mixtatin in irreversible pulpitis (2 arms), sponsored by Cairo University. Primary endpoint: Clinical success at 12 months. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
3Mixtatin
03
Conditions
irreversible pulpitis
Beyond the preview
Go deeper on NCT06925490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06925490.